As of Jan 20
| -0.05 / -2.02%|
The 6 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 3.75, with a high estimate of 6.00 and a low estimate of 2.00. The median estimate represents a +54.32% increase from the last price of 2.43.
The current consensus among 9 polled investment analysts is to Hold stock in ImmunoGen Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.